Evoke Pharma Highlights GIMOTI as a Leading Solution for Gastroparesis Treatment as Domperidone Supply Ends
19. Dezember 2024 08:30 ET
|
Evoke Pharma, Inc.
FDA posts update as mechanism to obtain unapproved Domperidone expected to lose supply in early 2025 Gimoti remains only approved drug shown to reduce hospitalizations, emergency room and medical...
Global Gastroparesis Treatment Market to Surpass US$ 10,726.0 Million by 2030, Says Coherent Market Insights (CMI)
18. August 2022 09:30 ET
|
CMI
Seattle, Aug. 18, 2022 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global gastroparesis treatment market is estimated to be valued at US$ 8,061.9 million in 2022 and expected to...
CinDome Pharma Announces Start of Phase 2 Trial of Deuterated Domperidone (CIN-102)
19. September 2019 08:30 ET
|
CinRx Pharma
CINCINNATI, Sept. 19, 2019 (GLOBE NEWSWIRE) -- CinDome Pharma, Inc. (“CinDome”), a company whose lead product is deuterated domperidone (CIN-102), today announced that is has enrolled the first...
Neurogastrx Appoints Baxter Phillips III as President and Chief Executive Officer
03. November 2015 11:50 ET
|
Neurogastrx
CAMPBELL, Calif., Nov. 03, 2015 (GLOBE NEWSWIRE) -- Neurogastrx, a biopharmaceutical company engaged in developing novel drugs for gastrointestinal disorders, today announced the appointment of...